About SWECARNET
Sweden’s network for clinical use of CAR T cells.
SWECARNET was established in 2019 by the SDP5 Swelife-ATMP project of the same name. Coordinated by the Centre for Cell therapy and Allogeneic Stem cell Transplantation (CAST) at Karolinska University Hospital, the network brings together those in Sweden developing, implementing or treating patients with Chimeric antigen receptor T (CAR T) cells. [Wikipedia]
Network partners
Uppsala Universitet, Skånes Universitetssjukhus, Sahlgrenska Universitetssjukhuset, Karolinska Institutet, Karolinska Universitetssjukhuset, Novartis Sverige AB, Celgene AB/BMS, Gilead Science Sweden AB, Jansen-Cilag AB och Läkemedelsindustriföreningen
SWECARNET is developing a bank of video resources to spread the word about CAR-T and the patient journey. View the the latest video or see the complete package here.
IN SWEDISH: from KUH/CAST doctors, nurses and nurses assistants on the patient experience of having life threatening disease and through CAST receiving possibly life saving treatments. Further, how it is to work in such a treatment environment, being a physchologist, friend and decision maker, combining resources and strategies, novel and standard, in high competence teamwork for the best of the patients.
Related content
Help us to revolutionise healthcare! Build a partnership with our organisation.
The ATMP newsletter is a quarterly newsletter updating on Swedish ATMP developments.